MDxHealth: Bleichroeder reports 32.04% stake

Accounts and funds managed by Bleichroeder LP report an aggregate acquisition cost of $46,267,320.19 for the shares.

Rhea-AI Filing Summary

MDxHealth SA's amended ownership disclosure reports that Bleichroeder, Bleichroeder Holdings LLC and Andrew Gundlach, identified as Chairman and CO-CEO, each beneficially own 30,571,922 ordinary shares, representing 32.04% of the outstanding shares. The reporting persons have sole voting and dispositive power over those shares.

Accounts and funds managed by Bleichroeder LP hold the shares, which were acquired on the open market and in transactions with MDxHealth at an aggregate cost of $46,267,320.19. Transactions reported for the past 60 days were all in the open market, and the per-share prices include commissions.

Key Figures

Beneficially owned ordinary shares: 30,571,922 shares Outstanding shares represented: 32.04% Aggregate cost: $46,267,320.19

3 metrics

Beneficially owned ordinary shares 30,571,922 shares Reported by each reporting person

Outstanding shares represented 32.04% Beneficial ownership reported by each reporting person

Aggregate cost $46,267,320.19 Cost of shares held by accounts and funds managed by Bleichroeder LP

Key Terms

beneficially own, sole voting power, sole dispositive power, aggregate cost

4 terms

beneficially own financial

"the Reporting Persons beneficially own 30,571,922.00 Shares"

Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

sole voting power financial

"The Reporting Persons have sole voting and dispositive power"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

sole dispositive power financial

"The Reporting Persons have sole voting and dispositive power"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

aggregate cost financial

"at an aggregate cost of $46,267,320.19"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MDxHealth (MDXH) shares do the reporting persons beneficially own?

Bleichroeder, Bleichroeder Holdings LLC and Andrew Gundlach each reported beneficial ownership of 30,571,922 ordinary shares, representing 32.04% of MDxHealth's outstanding shares. They reported sole voting and dispositive power over those shares.

What was the aggregate cost of the MDXH shares?

Accounts and funds managed by Bleichroeder LP acquired the 30,571,922 shares at an aggregate cost of $46,267,320.19. The shares were acquired on the open market and in transactions with MDxHealth.

How were recent MDXH share transactions made?

All transactions with respect to the shares reported for the past 60 days were effected in the open market. Per-share prices include any commissions paid.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 04:08 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:08 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)

MDxHealth SA

(Name of Issuer)

Ordinary Shares

(Title of Class of Securities)

58286E102

(CUSIP Number)

Bleichroeder LP
1345 Avenue of the Americas, 48th Floor,
New York, NY, 10105
(212) 984-3815

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/13/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

schemaVersion:

SCHEDULE 13D

CUSIP Number(s): 58286E102

1

Name of reporting person

Bleichroeder LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 30,571,922.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 30,571,922.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

30,571,922.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

32.04 %

14

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP Number(s): 58286E102

1

Name of reporting person

Bleichroeder Holdings LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 30,571,922.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 30,571,922.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

30,571,922.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

32.04 %

14

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13D

CUSIP Number(s): 58286E102

1

Name of reporting person

Andrew Gundlach

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 30,571,922.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 30,571,922.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

30,571,922.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

32.04 %

14

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Ordinary Shares
(b)	Name of Issuer: MDxHealth SA
(c)	Address of Issuer's Principal Executive Offices: CAP Business Center, Zone Industrielle des Hauts-Sarts, Herstal, BELGIUM , 4040.
Item 1 Comment: This Amendment No. 1 (this "Amendment") amends the Schedule 13D originally filed by the Reporting Persons with the Securities and Exchange Commission (the "SEC") on August 11, 2026 (the "Schedule 13D"), with respect to the ordinary shares (the "Shares"), of MDxHealth SA, a Belgium public limited liability company (the "Issuer"). Except as otherwise provided herein, each item of the Schedule 13D remains unchanged. Capitalized terms used herein but not otherwise defined shall have the meaning set forth in the Schedule 13D.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and restated as follows: Accounts and funds managed by the reporting person hold 30,571,922 Shares. The 30,571,922 Shares were acquired on the open market and in transactions with the Issuer by accounts and funds managed by Bleichroeder LP at an aggregate cost of $46,267,320.19.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a)-(c) of the Schedule 13D is hereby amended and restated as follows: As of the date of this Amendment, the Reporting Persons beneficially own 30,571,922.00 Shares, representing 32.04% of the outstanding Shares.
(b)	The Reporting Persons have sole voting and dispositive power over 30,571,922.00 Shares.
(c)	As of the date of this Amendment, Schedule I hereto sets forth all transactions with respect to the Shares effected by the Reporting Persons during the past sixty (60) days. All such transactions were effected in the open market, and per share prices include any commissions paid in connection with such transactions.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 99.1: Schedule I

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bleichroeder LP

Signature:	Andrew Gundlach
Name/Title:	Chairman and CO-CEO
Date:	10/15/2026

Bleichroeder Holdings LLC

Signature:	Andrew Gundlach
Name/Title:	Chairman and CO-CEO
Date:	10/15/2026

Andrew Gundlach

Signature:	Andrew Gundlach
Name/Title:	Chairman and CO-CEO
Date:	10/15/2026